Market Overview

UPDATE: Jefferies & Company Reiterates Hold Rating, Raises PT on Gilead Sciences

Related GILD
Technical Alert: Gilead Sciences Makes New For Move
Verastem's CEO Talks DYNAMO Study, The Competitive Landscape And Pitch To Investors
Buy Gilead's HIV Franchise And Get The Rest Of The Company For Free (Seeking Alpha)

In a report published Wednesday, Jefferies & Company reiterated its Hold rating on Gilead Sciences (NASDAQ: GILD), and raised its price target from $55.00 to $59.00.

Jefferies noted, “On its earnings call, GILD highlighted key interim Phase 3 data on 7977+5885 in 1Q13 (although GILD may not disclose it), as well as 12-week treatment data for 7977+ daclatasvir and ELECTRON data for 7977+5885 in GT1 naives (at AASLD in Nov), to determine the ideal 7977 regimen for GT1 HCV. We are positive on 7977 prospects and continue work on sizing the HCV market to better analyze valuation.”

Gilead Sciences closed on Tuesday at $64.91.

Latest Ratings for GILD

Nov 2016Stifel NicolausInitiates Coverage OnBuy
Nov 2016MizuhoInitiates Coverage OnBuy
Nov 2016BMO CapitalUpgradesMarket PerformOutperform

View More Analyst Ratings for GILD
View the Latest Analyst Ratings

Posted-In: Jefferies & CompanyAnalyst Color Price Target Analyst Ratings


Related Articles (GILD)

View Comments and Join the Discussion!